

Cambridge University Press

978-0-521-78561-7 - The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990

Harry M. Marks

Index

[More information](#)

INDEX

- Adams, David P., 106
 acquired immune deficiency syndrome, and
 clinical trials, 5, 13, 237–238, 240,
 243
 Ahrens, Edward H., Jr., 190
 Amberson, J. Burns, 124n114, 140n18
 American Medical Association and therapeutic
 reform, 11, 23–24, 35, 39, 76
 American Pediatric Society, 44–45
 Anderson, John F. 27
 animal experiments
 gonorrhoea, 100, 101
 syphilis, 107
 and therapeutic efficacy, 33–34
 see also arteriosclerosis, animal experiments
 Anitschkow, Nicolai N., 166–167
 antipyretics, 18, 80
 Arendt, Hannah, 238–239
 arsphenamine, *see* syphilis therapy, arsenicals;
 Cooperative Clinical Group study of
 syphilis therapy
 arteriosclerosis
 animal experiments, 166–167, 170
 models of, 166–167, 169, 170–171
 see also diet and heart disease
- Banting, Frederick G., 17
 Bartholow, Roberts, 21
 Bauer, Walter, 152, 153
 Berkson, Joseph, 251
 Bernard, Claude, 1n3, 21
 Bernoulli, Daniel, 235
 Bigelow, George H., 63
 biologicals (serums, vaccines, and hormones), 18,
 47–49, 73
 Biologics Control Act of 1902, 27, 73–74, 76
 Blake, Francis G., 62, 91
 Brown, Byron, 207
 Burnham, John C., 179n69, 242
 Bush, Vannevar, 98, 104–106, 250
- Calver, George W., 96
 Campbell, Walter G., 75
 Capps, Joseph A., 35
 Carlson, Anton J., 36
 Carpenter, Charles M., 101
 Cecil, Russell L., 65
 Chalmers, Thomas C., 2
 and University Group Diabetes Program,
 219, 220
 Cohn, Alfred E., 101
 Cole, Harold N., 54
 Cole, Rufus, 49, 60–62
 Coleman, William, 6
 collective investigation, 6, 43–45
 Commonwealth Fund, *see* pneumonia, serum
 therapy, Commonwealth Fund study of
 Cooperative Clinical Group study of syphilis
 therapy, 11, 53–59
 funding, 58–59
 individualism and, 56–57
 origins and organization, 53–55
 and practicing physicians, 54, 57–59
 and Public Health Service, 56, 57–59
 standardization, 55–56
 statisticians in, 56
 see also syphilis therapy, arsenicals
 cooperative research, 52–53
 cooperative studies, 6, 9, 11–12, 52–53, 69–70
 in World War II, 11–12, 99–100, 106, 108–
 110, 113
 post–World War II, 12, 113–114, 115, 121,
 125–128, 132
 Copeland, Senator Royal S., 75
 Cornfield, Jerome, 153n80, 251
 and Diet-Heart study, 183, 184, 185, 186
 and University Group Diabetes Program,
 207, 208n41, 212, 215n74, 220
 Coronary Drug Project, 192–193, 195
 Council on Pharmacy and Chemistry, 2, 3, 11,
 72, 74, 132, 230, 235, 237, 249–250

Cambridge University Press

978-0-521-78561-7 - The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990

Harry M. Marks

Index

[More information](#)254 *Index*

- Council on Pharmacy and Chemistry (*cont.*)
and American Medical Association Board of Trustees, 35, 39
animal experiments, as evidence, 33–34
anticommercialism, 25, 26, 32–33, 35, 37–39
and Ceanothyn, 35–36
character and evidence, 22, 25, 27, 32, 40
chemical laboratory studies, as evidence, 32–33
clinical studies, as evidence, 34–36
and educational reform, 27–28
and Food and Drug Administration, 27, 76, 94
origins, 22–25
post–World War II, 133, 147–148, 159
and practicing physicians, 26–27, 29–30, 38, 40–41
and sulfanilamide, 80
and sulfapyridine, 84, 88
Therapeutic Trials Committee, 147–148, 158n104
and tolbutamide, 203n24
see also rational therapeutics; therapeutic reform
- Cox, Gertrude M., 252
- Cushny, Arthur R., 24
- D’Alembert, Jean, 235
- diabetes
complications, 201–202
Diabetes Control and Complications Trial, 201n17, 228
insulin therapy, 17, 18, 52, 200–201, 202
and Joslin Diabetes Clinic, 201–202, 216
oral hypoglycemic therapy, 197, 203–204, 227–228
pathophysiology, 200–201
therapeutic philosophies, 201–202
see also University Group Diabetes Program
- diet and heart disease
and American diet, 164–165, 173, 176, 180
and epidemiological studies, 172–173, 174–176, 178, 194–195
and laboratory studies, 174, 180
medical attitudes, 165, 178–180
pre–World War II views, 168, 169
scientific controversies, 169–171, 176
see also arteriosclerosis; Diet-Heart study; heart disease; Keys, Ancel; Stamler, Jeremiah
- Diet-Heart study, 12, 134, 165, 181–196
aims and origins, 181–184
and clinical trials, 134, 184–185, 195–196
“double-blinding,” 185, 187, 189
and laboratory researchers, 183, 190, 191
and National Heart Institute, 183, 187n102, 191n117
and National Institutes of Health, 187, 190–192, 195
and public health policy, 179, 193–194, 196
pilot study, 188–189
social engineering, 185–186
statisticians and, 183, 184, 185, 195
study design, 184–187
see also diet and heart disease; Keys, Ancel; Page, Irvine H.; Stamler, Jeremiah
- diphtheria antitoxin, 17, 45, 47
- disciplines, 2–3, 45, 149, 162, 177–178; *see also* epidemiology, discipline; statistics
- Dorn, Harold, 154n84, 251
- drug manufacturers, 18, 25, 50
and Food and Drug Administration, 76, 81, 89, 95–97
promotional activities, 19–20, 27, 35, 38–39, 223
research, 55, 58–59, 68, 94n99, 107, 114, 126, 147–148, 149, 161n119
- drugs, controls on use, 4, 5, 41, 80, 81, 85–88, 92, 95, 224, 226
see also therapeutic reform, and practicing physicians
- drugs, risk–benefit, 4–5, 72, 90, 91–92, 95–96
and University Group Diabetes Program, 208, 210–211, 215
- drugs, safety, 33, 71–72, 78–79, 85, 89–90, 96–97; *see also* pneumonia, serum therapy; sulfa drugs; syphilis therapy, arsenicals; University Group Diabetes Program
- Dublin, Louis Israel, 137n4, 164–165
- Durrett, James J., 78
- Edsall, David L., 32n59, 35
- Ehrlich, Paul, 51–52, 54, 113
- epidemiology, discipline, 138n11, 177–178
- Epstein, Steven Gary, 13
- Federal Food, Drug and Cosmetic Act of 1938, 11, 71–72
legislative origins, 71n3, 75–77, 81n81
see also Food and Drug Administration
- Feinstein, Alvan R.
and clinical research, 213–215
and methodological reform, 213–215, 224
and University Group Diabetes Program, 204n44, 213–215, 224
- Feldman, William H., 114
- Felton, Lloyd D., 62
- Fishbein, Morris, 158
- Fisher, Ronald Aylmer, 10, 130, 143
and randomized experiments, 138, 141–145, 147, 212, 244
- Flexner, Simon, 47n20, 49–50
- Food and Drug Administration, 3, 11, 75, 230, 250

Cambridge University Press

978-0-521-78561-7 - The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990

Harry M. Marks

Index

[More information](#)*Index*

255

- academic advisors, 86–88, 90–92, 93–94
and controlled clinical trials, 129, 133,
159n110, 218, 230, 237–238, 240
drug-labeling policies 73, 74, 80–81, 95–97
drugs, efficacy, 71, 75, 96–97, 129
drugs, risk–benefit, 3, 72, 90, 91–92, 95–96
drugs, safety, 71–72, 78, 83–85, 89–90
and glandular products, 96–97
laboratory studies, as evidence, 75, 78, 83–84,
85, 96
legal authority, 74–77, 97
and medical practice, 73, 82, 89, 92, 94–96
regulatory philosophy, 77, 80n38, 89, 90, 92–
94, 97
and sulfapyridine, 83–92
and therapeutic reform, 72–73, 78–79, 79,
94–95
thiouracil, 80n38
and University Group Diabetes Program,
197, 199, 216, 218, 219, 224–225, 227–
228
see also Biologics Control Act of 1902; Fed-
eral Food, Drug and Cosmetic Act of
1938; Pure Food and Drug Act of 1906
- Fox, Renée C., 239
Frantz, Ivan D., 183, 184, 188n103, 194n126, 128
Fredrickson, Donald S., 133, 190, 193n122
Fried, Charles, 14n35
- glandular products, 33, 96–97
gonorrhoea, therapy, World War II studies
animal experiments, 100, 101
human experiments, 101, 103–105
Green, Jerome, 183–185
Greenberg, Bernard G., 252
- Harrison, Ross G., 104, 105
Hatcher, Robert A., 24, 34n72, 36
heart disease
acute care, 168–169
drug therapy, 168, 192–193
epidemiology, 164, 172–176, 178
President Eisenhower, 176
prevention, 169, 192–193
“pump” model, 167–168
see also arteriosclerosis; diet and heart disease;
Diet-Heart study
- Heffron, Roderick, 63, 66
Hench, Philip S., 251
Hill, A. Bradford
and randomized experiments, 144–147, 156,
212
Hill, Justina H., 100, 101
Hinshaw, H. Corwin, 114
Hogben, Lancelot, 160n117, 162n122
Hughes, Elizabeth Evans, 17
human experimentation, ethics
Institutional Review Boards, 239–240
prisoners, 101–102, 103–105
Public Health Service, tuberculosis studies,
122–124
and randomized clinical trials, 155–158, 207–
208, 232–233
Veterans Administration, tuberculosis studies,
116–119
in World War II, 101–105
Hygienic Laboratory, 48, 73–74
- Jewett, Frank B., 103–105
- Keefer, Chester Scott, 106–108, 114, 234
Keys, Ancel B.
and American diet, 175, 180, 193–194
critics of, 177–179
and Diet-Heart study, 183–184, 186,
188n103
and “double-blinding,” 186, 189
and epidemiological studies, 173–175, 178,
180
and laboratory physiology, 173–174
training, 173
Klimt, Christian R., 204, 206, 223
Klumpp, Theodore G., 78–79, 82, 88–89
Knowles, Harvey C., 204–205
- laboratory sciences, 1–2, 8, 18, 21, 28, 30, 45,
49–51, 58, 68, 137, 171–172, 173–174,
182, 191, 234–235
Liebenau, Jonathan M., 73
Lind, James, 5–6
Long, Perrin H., 87, 91n91, 106
Löwy, Ilana, 13
- Mahoney, John F., 105, 107
Mainland, Donald, 152, 153, 154n86, 251
Mann, George V., 183
Mantel, Nathan, 251
Marshall, Eli Kennerly, Jr., 88, 145n35
Marston, Robert Q., 191, 219
McCoy, George, 27, 74
medical profession, divisions in, 4, 23, 30, 46,
50–51, 61, 231
see also therapeutic reform, and practicing
physicians
- Meier, Paul, 16n35,
and University Group Diabetes Program,
212, 220n101, 225
Meldrum, Marcia, 13
Merck & Company, 84
Merrell, Margaret, 115n72, 122, 136n4
Merriam, John C., 52
Metropolitan Life Insurance Company, 65,
164
Miller, Max, 204, 208n41, 210

Cambridge University Press

978-0-521-78561-7 - The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990

Harry M. Marks

Index

[More information](#)256 *Index*

- Moore, Felix E., 183, 184
 Moore, Joseph Earle, 54, 56, 59, 102, 108
- National Academy of Sciences
 and drug evaluation, 147
see also gonorrhoea, therapy, World War II studies
- National Cancer Institute, 13, 132
- National Heart Institute
 and Congress, 171
 and laboratory sciences, 171-172
see also Diet-Heart study
- National Institutes of Health, 12, 111, 152-154, 250; *see also* Diet-Heart study; Hygienic Laboratory; University Group Diabetes Program
- Nelson, Senator Gaylord, 225
- Neyman, Jerzy, 10, 130
- National Research Council, 52, 98-99, 103, 105
 Committee on Venereal Disease, 100-102, 108
 drug evaluation, 133, 147-148
 postwar medical research, 113, 114
see also human experimentation, ethics; syphilis therapy, penicillin studies
- O'Leary, Paul A., 54
- objectivity in research, 33-34, 124-125, 133, 206, 214-215, 246
 bias, 37, 53, 122, 144-146, 211, 234, 244
 "blinded" studies, 36, 38, 133, 156n93, 185-186, 187, 189, 205
 personal equation, 42
- Office of Scientific Research and Development, 12, 98, 103-105
- Office of Scientific Research and Development, Committee on Medical Research, 12, 99, 102-103, 111
 gonorrhoea studies, 100-105
 penicillin program, 105, 106
see also syphilis therapy, penicillin studies
- organizational synthesis, 7, 68
- Page, Irvine H., 189, 193
 and Diet-Heart study, 181-183
 and dietary policy, 182, 193, 194
- Palmer, Caroll E., 115n72, 117n84, 122
- Palmer, Walter L., 36
- Paris clinical school, 6, 43
- Parran, Thomas, Jr., 54, 57, 58, 65
- Pearson, Egon S., 130
- Pincus, Gregory G., 250
- pneumonia, serum therapy, 11, 49, 60-62, 84
 costs, 61
 improvements in, 62, 64-65
 and laboratory diagnosis, 61
 risks, 60-61
- pneumonia, serum therapy, Commonwealth Fund study of, 11, 62-67
 aims, 63, 67, 69
 consultants in, 63-64
 in Massachusetts, 62-65, 66
 and Massachusetts Department of Public Health, 62-65
 and Metropolitan Life Insurance Co., 65
 in New York state, 65-67
 and New York State Health Department, 65-66
 and New York State Medical Society, 65-66
 and practicing physicians, 64-67, 69
 and rational therapeutics, 63-64, 69
- pneumonia, sulfapyridine therapy, 67, 83-89, 90-92
 risk-benefit, 86-87, 90
 safety, 83-85
- polio, Salk vaccine, field trials, 13, 159-160, 179n69
- Porter, Theodore M., 244
- Public Health Service, 111; *see also* Cooperative Clinical Group study of syphilis therapy; tuberculosis, streptomycin studies (Public Health Service)
- Pure Food and Drug Act of 1906, 27, 74-75
- randomized clinical trials, 3, 132, 133, 150, 151, 157n100, 159, 227
 in chronic disease, 161-162
 and clinical controversies, 4-5, 134-135, 150-151, 159-160, 233-234; *see also* Diet-Heart study; University Group Diabetes Program
 and clinical knowledge, 145, 155, 156-157, 160-161; *see also* University Group Diabetes Program
 conflicting aims, 159-160, 195-196, 226-227, 244
 ethics, 155-158, 207-208, 232-233
 and Food and Drug administration, 129, 133, 218, 230, 237-238, 240
 historiography, 5-6, 13, 133n14, 140n18
 randomization and, 138, 140n18, 141-148, 155-157, 211-212, 221, 224, 244-245
 social analysis, 134-135, 160, 240-245
 and statistical inference, 132, 162-163, 198, 207, 221-222, 232-233
 women and minorities, 237, 240-243
see also Diet-Heart study; statistics; University Group Diabetes Program
- rational therapeutics, 21-22, 26, 32-33, 63-64, 67, 69, 72, 75, 110-111
 and antibiotics, 149-150
 post-World War II, 149-150, 233-234
see also Council on Pharmacy and Chemis-

Cambridge University Press

978-0-521-78561-7 - The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990

Harry M. Marks

Index

[More information](#)

Index

257

- try; Food and Drug Administration; therapeutic reform
- republic of science, 4, 230–232
- Richards, A. Newton, 103, 104, 106, 250
- Rockefeller Institute for Medical Research, 48–50, 60, 182
- Rosenberg, Charles, 15
- Rothman, David J., 105n34, 157n101
- Russell Sage Institute of Pathology, 50
- S. E. Massengill Company, 82
- Savage, Leonard J., 10
- science and character, 22, 25, 27, 29, 30, 32, 37, 38, 40, 91
- science and politics, 5, 15–16, 230, 231, 233–234, 237–244
- deliberation, 246–248
- democratic forums, 245–248
- science and rationing, 106–107, 108, 109, 110–111, 114–115, 117–120, 122–123, 126–127, 234, 236
- scientific controversies, 231–233
- scientific medicine, 1, 2, 4, 231
- Shannon, James A., 187, 191
- Shewart, Walter A., 242
- Shimkin, Michael, 156
- Simmons, George H., 23–25, 39, 41
- Simmons, Henry, 216
- smallpox inoculation debates, 130n4, 234
- sociology of science, 8–10, 149, 199, 223, 234n14, 243
- Sollman, Torald H., 2, 24–26, 36, 54, 158
- Stamler, Jeremiah, 176, 181
- and American diet, 175, 180, 193
- and Diet-Heart study, 181–183
- and dietary policy, 193
- and “double-blinding,” 186
- and multiple intervention studies, 195
- Stanley, Manfred, 245
- Stare, Frederick J., 183–184
- statistics
- discipline, 131, 137–138, 148–149
- historiography, 10, 130–132, 133n14, 242n43
- statistical inference, 130n5, 162–163
- twentieth century, 130–131
- statistics in medicine, 130, 133–134, 135, 136–137, 158, 251–252
- and clinical knowledge, 160–162, 213–215, 234, 244–245
- limits of, 154–155, 232–233, 242
- and medical research, 148–149, 151–154, 159–160; *see also* Diet-Heart study; University Group Diabetes Program
- pre-World War II, 130, 136, 139–141, 148
- statisticians, training of, 153–154
- statisticians, women as, 136
- and therapeutic reform, 138, 149, 151, 155, 226–227
- see also* objectivity in research; randomized clinical trials; therapeutic research
- Stokes, John H., 53
- Stormont, Robert T., 97
- streptomycin, *see* tuberculosis, streptomycin studies
- sulfa drugs, 79–80
- controls on use, 80
- Elixir Sulfanilamide, 82
- sulfanilamide, 79
- sulfapyridine 67, 83–84; *see also* pneumonia, sulfapyridine therapy
- sulfathiazole, 101
- syphilis therapy, arsenicals, 11, 51–52, 54–56, 57–58
- see also* Cooperative Clinical Group study of syphilis therapy; Ehrlich, Paul
- syphilis therapy, penicillin studies, 107–113
- origins and aims, 106–108
- and practicing physicians, 110–111, 113
- and Public Health Service, 111
- science and rationing, 106–107, 108, 109, 110–111
- standardization, 109–110, 111
- statisticians, 111, 112
- therapeutic authority, 45, 69, 70, 133
- and statistics, 161–162
- therapeutic nihilism, 20, 21, 150–151
- therapeutic reform, 3–5
- anticommercialism, 3, 20, 25, 26, 32–33, 35, 37–39, 150, 223, 233–234
- history and policy, 229–230, 248
- institutions and authority, 132–133, 231, 234, 237, 242, 246–248
- methodological reform, 3, 10, 133, 135, 150, 154, 157, 159, 230, 232, 236–237, 242
- nineteenth-century, 20, 21, 23
- and practicing physicians, 22, 31–32, 81–82, 92, 149–150, 230, 233–234
- therapeutic research, 12–13
- and clinical experience, 3, 30, 42–43, 46, 91, 140–141
- controls in, 5, 30–31, 49–50, 60n76, 88, 90–91, 102, 139–141, 145–146; 158; *see also* randomized clinical trials; tuberculosis, streptomycin studies
- drug manufacturers and, 55, 58–59, 68, 94n99, 107, 114, 126, 147–148, 149, 161n119
- hospitals and, 31, 43, 44, 46, 49–50
- and philanthropic foundations, 69; *see also* pneumonia, serum therapy, Commonwealth Fund study of
- public health laboratories, 47–48

Cambridge University Press

978-0-521-78561-7 - The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990

Harry M. Marks

Index

[More information](#)258 *Index*

- therapeutic research (*cont.*)
 university-based, 50–51
 in World War II, 98–99; *see also* gonorrhea,
 therapy, World War II studies; syphilis
 therapy, penicillin studies
see also objectivity in research
- therapeutic revolution, 15, 18
- Tröhler, Ulrich, 6
- tuberculosis, streptomycin studies (Public Health Service), 121–126, 132
 and Bureau of the Budget, 122
 controls in, 122–124
 funding, 121–122
 objectivity, 124–125
 origins, 121
 science and rationing, 122–123
 standardization, 121, 124
 statisticians, 122, 125
see also tuberculosis, streptomycin therapy;
 cooperative studies
- tuberculosis, streptomycin studies (Veterans Administration), 116–120
 Bureau of the Budget, 120
 controls in, 116–117, 118
 science and rationing, 117–120
 standardization, 118–120
 and VA lobby, 116, 117, 119
see also tuberculosis, streptomycin therapy, cooperative studies
- tuberculosis, streptomycin therapy (Medical Research Council), 6, 127n125, 132, 144–145n34
- tuberculosis, streptomycin therapy, cooperative studies, 12, 113–228
 funding, 126
 methodological reform, 127–128
 origins, 114–116
 randomization, 127
 science and rationing, 114–115, 126
 standardization, 126–128
 statistics, 128
see also tuberculosis, streptomycin studies (Public Health Service); tuberculosis, streptomycin studies (Veterans Administration)
- Tugwell, Rexford, 75
- Tukey, John W., 252
- University Group Diabetes Program, 12, 134, 204–228 231, 232
 American Diabetes Association, 209
 and Biometric Society, 220–222
 critics of, 211–216, 221n106, 222, 223–224
 critics and Food and Drug Administration, 217–219
 early stopping, 207–208
 influence, 227–228
 and methodological reform, 197–198, 205, 213–215, 219–224, 226
 and National Institute of Arthritis and Metabolic Diseases, 218–219
 and National Institutes of Health, 197, 220–221
 randomization, 211–212, 221, 224
 and scientific controversies, 198–199, 209–210, 225–226
 study design, 204–206
 and therapeutic authority, 198, 222
 tolbutamide mortality, 206–209, 212–213
 Upjohn Company, 203, 209n44, 218n87, 250
see also diabetes
- Veterans Administration 12, 132; *see also* tuberculosis, streptomycin studies (Veterans Administration)
- Voegtlin, Carl, 48
- Waksman, Selman A., 113
- War Production Board, 106
- Warner, John Harley, 21
- Weed, Lewis H., 99
- Weisz, George, 6
- Whedon, Donald, 209n44, 218
- White, Benjamin, 65
- Wile, Udo J., 54
- Wiley, Harvey W., 27
- Wood, Horatio C., 21
- Zelen, Marvin, 220n101